These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 1974511)

  • 1. The pharmacology of carvedilol.
    Ruffolo RR; Gellai M; Hieble JP; Willette RN; Nichols AJ
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S82-8. PubMed ID: 1974511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
    Nichols AJ; Gellai M; Ruffolo RR
    Fundam Clin Pharmacol; 1991; 5(1):25-38. PubMed ID: 1712335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol.
    Nichols AJ; Sulpizio AC; Ashton DJ; Hieble JP; Ruffolo RR
    Pharmacology; 1989; 39(5):327-36. PubMed ID: 2575762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical pharmacology of carvedilol.
    Ruffolo RR; Boyle DA; Venuti RP; Lukas MA
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S2-15. PubMed ID: 8487245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors.
    Nichols AJ; Sulpizio AC; Ashton DJ; Hieble JP; Ruffolo RR
    Chirality; 1989; 1(4):265-70. PubMed ID: 2577144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
    Feuerstein GZ; Ruffolo RR
    Eur Heart J; 1996 Apr; 17 Suppl B():24-9. PubMed ID: 8733068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic profile of carvedilol.
    van Zwieten PA
    Cardiology; 1993; 82 Suppl 3():19-23. PubMed ID: 8106159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.
    Yue TL; Cheng HY; Lysko PG; McKenna PJ; Feuerstein R; Gu JL; Lysko KA; Davis LL; Feuerstein G
    J Pharmacol Exp Ther; 1992 Oct; 263(1):92-8. PubMed ID: 1357162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.
    Bril A; Slivjak M; DiMartino MJ; Feuerstein GZ; Linee P; Poyser RH; Ruffolo RR; Smith EF
    Cardiovasc Res; 1992 May; 26(5):518-25. PubMed ID: 1359930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils.
    Yue TL; McKenna PJ; Ruffolo RR; Feuerstein G
    Eur J Pharmacol; 1992 Apr; 214(2-3):277-80. PubMed ID: 1355437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of carvedilol.
    Tomlinson B; Prichard BN; Graham BR; Walden RJ
    Clin Investig; 1992; 70 Suppl 1():S27-36. PubMed ID: 1350481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils.
    Yue TL; McKenna PJ; Gu JL; Cheng HY; Ruffolo RE; Feuerstein GZ
    Cardiovasc Res; 1994 Mar; 28(3):400-6. PubMed ID: 7909721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
    Bristow MR; Larrabee P; Müller-Beckmann B; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port JD
    Clin Investig; 1992; 70 Suppl 1():S105-13. PubMed ID: 1350478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.
    Sponer G; Bartsch W; Strein K; Müller-Beckmann B; Böhm E
    J Cardiovasc Pharmacol; 1987 Mar; 9(3):317-27. PubMed ID: 2437399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture.
    Saijonmaa O; Metsärinne K; Fyhrquist F
    Blood Press; 1997 Jan; 6(1):24-8. PubMed ID: 9116922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery.
    Hattori Y; Nakaya H; Endou M; Nakao Y; Kanno M
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):572-9. PubMed ID: 2470994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats.
    Okajima K; Harada N; Uchiba M; Isobe H
    J Pharmacol Exp Ther; 2004 May; 309(2):684-91. PubMed ID: 14764656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-thrombotic effects of nebivolol and carvedilol: Involvement of β2 receptors and COX-2/PGI2 pathways.
    Kozlovski VI; Lomnicka M; Bartus M; Sternak M; Chlopicki S
    Pharmacol Rep; 2015 Oct; 67(5):1041-7. PubMed ID: 26398401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.